Thomas Frisell1, Karin Hellgren2, Lars Alfredsson3, Soumya Raychaudhuri4, Lars Klareskog5, Johan Askling2. 1. Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Solna, Sweden. 2. Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Solna, Sweden Rheumatology Unit, Department of Medicine, Karolinska Institutet, Solna, Sweden. 3. Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 4. Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, USA Arthritis Research UK Epidemiology Unit, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, UK. 5. Rheumatology Unit, Department of Medicine, Karolinska Institutet, Solna, Sweden.
Abstract
OBJECTIVES: Our objective was to estimate the risk of developing rheumatoid arthritis (RA) associated with a family history of non-RA arthritis-related diseases. This familial co-aggregation is of clinical interest since it is often encountered when assessing family history of RA specifically, but also informative on the genetic overlap between these diseases. Since anticitrullinated peptide antibodies/rheumatoid factor (RF)-positive and RF-negative RA have both specific and shared genetic factors, the familial co-aggregation was assessed separately for seropositive and seronegative disease. METHODS: Nested case-control study in prospectively recorded Swedish total population data. The Multi-Generation Register identified first-degree relatives. RA and arthritis-related diseases were ascertained through the nationwide patient register. RA serology was based on International Classification of Diseases tenth revision coded diagnoses, mainly reflecting RF. Familial risks were calculated using conditional logistic regression. Results were replicated using the Swedish rheumatology register. RESULTS: Familial co-aggregation was found between RA and every studied arthritis-related disease, but the magnitude varied widely, from juvenile idiopathic arthritis (JIA) (seropositive RA OR=3.98 (3.01 to 5.26); seronegative RA OR=5.70 (3.47 to 9.36)) to osteoarthritis (seropositive RA OR=1.03 (1.00 to 1.06); seronegative RA OR=1.05 (1.00 to 1.09)). The familial co-aggregation pattern of non-RA arthritis-related diseases was overall similar for seropositive and seronegative RA. Among those with family history of RA, relatives' other arthritis-related diseases conferred little or no additional risk. CONCLUSIONS: Although family history of several arthritis-related diseases may be useful to predict RA (eg, lupus and JIA), others (eg, osteoarthritis and arthralgia) are less useful. Seropositive and seronegative RA had rather similar familial co-aggregation patterns with arthritis-related diseases, suggesting that the two RA subsets are similar in the genetic factors that overlap with these diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
OBJECTIVES: Our objective was to estimate the risk of developing rheumatoid arthritis (RA) associated with a family history of non-RA arthritis-related diseases. This familial co-aggregation is of clinical interest since it is often encountered when assessing family history of RA specifically, but also informative on the genetic overlap between these diseases. Since anticitrullinated peptide antibodies/rheumatoid factor (RF)-positive and RF-negative RA have both specific and shared genetic factors, the familial co-aggregation was assessed separately for seropositive and seronegative disease. METHODS: Nested case-control study in prospectively recorded Swedish total population data. The Multi-Generation Register identified first-degree relatives. RA and arthritis-related diseases were ascertained through the nationwide patient register. RA serology was based on International Classification of Diseases tenth revision coded diagnoses, mainly reflecting RF. Familial risks were calculated using conditional logistic regression. Results were replicated using the Swedish rheumatology register. RESULTS: Familial co-aggregation was found between RA and every studied arthritis-related disease, but the magnitude varied widely, from juvenile idiopathic arthritis (JIA) (seropositive RA OR=3.98 (3.01 to 5.26); seronegative RA OR=5.70 (3.47 to 9.36)) to osteoarthritis (seropositive RA OR=1.03 (1.00 to 1.06); seronegative RA OR=1.05 (1.00 to 1.09)). The familial co-aggregation pattern of non-RA arthritis-related diseases was overall similar for seropositive and seronegative RA. Among those with family history of RA, relatives' other arthritis-related diseases conferred little or no additional risk. CONCLUSIONS: Although family history of several arthritis-related diseases may be useful to predict RA (eg, lupus and JIA), others (eg, osteoarthritis and arthralgia) are less useful. Seropositive and seronegative RA had rather similar familial co-aggregation patterns with arthritis-related diseases, suggesting that the two RA subsets are similar in the genetic factors that overlap with these diseases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Authors: C Bengtsson; A Berglund; M-L Serra; L Nise; B Nordmark; L Klareskog; L Alfredsson Journal: Scand J Rheumatol Date: 2010-08 Impact factor: 3.641
Authors: S F Grant; G Thorleifsson; M L Frigge; J Thorsteinsson; B Gunnlaugsdóttir; A J Geirsson; M Gudmundsson; A Vikingsson; K Erlendsson; J Valsson; H Jónsson; D F Gudbjartsson; K Stefánsson; J R Gulcher; K Steinsson Journal: Arthritis Rheum Date: 2001-10
Authors: Aase Haj Hensvold; Patrik K E Magnusson; Vijay Joshua; Monika Hansson; Lena Israelsson; Ricardo Ferreira; Per-Johan Jakobsson; Rikard Holmdahl; Lennart Hammarström; Vivianne Malmström; Johan Askling; Lars Klareskog; Anca Irinel Catrina Journal: Ann Rheum Dis Date: 2013-11-25 Impact factor: 19.103
Authors: Eva Baecklund; Anastasia Iliadou; Johan Askling; Anders Ekbom; Carin Backlin; Fredrik Granath; Anca Irinel Catrina; Richard Rosenquist; Nils Feltelius; Christer Sundström; Lars Klareskog Journal: Arthritis Rheum Date: 2006-03
Authors: Henrik Kallberg; Leonid Padyukov; Robert M Plenge; Johan Ronnelid; Peter K Gregersen; Annette H M van der Helm-van Mil; Rene E M Toes; Tom W Huizinga; Lars Klareskog; Lars Alfredsson Journal: Am J Hum Genet Date: 2007-04-02 Impact factor: 11.025
Authors: Diane van der Woude; Jeanine J Houwing-Duistermaat; René E M Toes; Tom W J Huizinga; Wendy Thomson; Jane Worthington; Annette H M van der Helm-van Mil; René R P de Vries Journal: Arthritis Rheum Date: 2009-04
Authors: Chang-Fu Kuo; Matthew J Grainge; Ana M Valdes; Lai-Chu See; Kuang-Hui Yu; S W Steven Shaw; Shue-Fen Luo; Weiya Zhang; Michael Doherty Journal: Rheumatology (Oxford) Date: 2017-06-01 Impact factor: 7.580
Authors: M De Santis; A Ceribelli; F Cavaciocchi; E Generali; M Massarotti; N Isailovic; C Crotti; H U Scherer; C Montecucco; C Selmi Journal: Clin Exp Immunol Date: 2016-07-25 Impact factor: 4.330
Authors: Peter A Nigrovic; Robert A Colbert; V Michael Holers; Seza Ozen; Nicolino Ruperto; Susan D Thompson; Lucy R Wedderburn; Rae S M Yeung; Alberto Martini Journal: Nat Rev Rheumatol Date: 2021-03-17 Impact factor: 20.543
Authors: Vanessa L Kronzer; Cynthia S Crowson; Jeffrey A Sparks; Elena Myasoedova; John Davis Journal: Arthritis Care Res (Hoboken) Date: 2021-02 Impact factor: 4.794